CDK4 and CDK6, therefore, emerged as viable therapeutic targets, and evaluation of CDK4 and 6 inhibitors in combination with other therapies is an area of active investigation that is changing the treatment landscape for HR+, HER2- advanced breast cancer. Here, ERBB2 is linked to breast carcinoma.